ReviewInternational journal of nanomedicine2025
How Effective are Key Phytocompound Carrying Polysaccharide Nanocarriers as Anti-Breast Cancer Therapy? A Comprehensive Review of the Literature.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Harnessing Nanocarriers to Improve Psychiatric Treatment: Progress, Limitations, and Future Directions.International journal of nanomedicine · 2026Review
- Nanoformulated Terpenoids in Cancer: A Review of Therapeutic Applications, Mechanisms, and Challenges.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer continues to be one of the most perilous diseases globally due to the challenges in identifying cost-effective and targeted targets for effective treatment strategies. In response to these unmet demands, much research has focused on investigating the anti-breast cancer properties of natural compounds due to their multi-target modes of action and favorable safety profiles. Numerous extracts of medicinal plants, essential oils, and natural bioactive substances have exhibited anticancer properties in preclinical breast cancer models. Nonetheless, the clinical utilization of therapies based on natural chemicals is constrained by challenges such as inadequate solubility and permeability. Innovative drug delivery systems utilizing nanoparticles are currently being investigated as adaptable solutions to overcome these limitations. Polysaccharide-based nanoparticles exhibit promising biodegradability and biocompatibility, making them suitable for targeted drug delivery systems among the diverse nanocarrier types. Many polysaccharide nanocarriers, including chitosan, hyaluronic acid, cellulose, starch, and complex polysaccharides, have been shown to enhance the bioavailability and therapeutic effectiveness of phytocompounds. This review examines the anticancer properties of phytocompounds and polysaccharide nanocarriers in breast cancer before focusing on the use of polysaccharide-based nanocarriers to deliver phytocompounds for the treatment of breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.